A generic alternative indicated for Asthma, Breathing and COVID-19. This formulation supports the reduction of lung tissue scarring to facilitate improved oxygen intake.
Formulated to alleviate lung function decline by addressing fibrous tissue growth to support respiratory stability and mitigate disease progression in pulmonary fibrosis patients.
Mechanism of Action
Pirfenidone reduces the production of proteins that lead to scarring and inflammation in the lungs. It blocks the activity of growth factors that signal fibroblasts to multiply and deposit excess collagen.
Route of Administration
Oral
Onset Time
Steady state in 2 days; months for response
Duration
8 hours
Contraindications
Severe hepatic impairment, Severe renal failure requiring dialysis, Concurrent use with fluvoxamine
Severe Adverse Events
Severe liver toxicity, Elevated liver enzymes, Severe photosensitivity reactions, Gastrointestinal perforation, Angioedema
Information for Esbriet is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
